Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908404 | 0.83 | LMNA (0.43) | CYP2C9CYP2C19 | |
| SCHEMBL3906369 | 0.78 | MEN1 (0.42) | — | |
| SCHEMBL3908850 | 0.78 | NOTUM (0.34) | CRHR1DRD2 | |
| SCHEMBL3897965 | 0.77 | DRD2 (0.49) | DRD2HTR2ADRD3 | |
| SCHEMBL3905333 | 0.75 | DRD2 (0.31) | DRD2HTR2ADRD3 | |
| SCHEMBL3911913 | 0.75 | CCR10 (0.33) | — | |
| SCHEMBL3899711 | 0.75 | CCR10 (0.33) | — | |
| SCHEMBL3911721 | 0.74 | RORC (0.33) | — | |
| SCHEMBL3897928 | 0.74 | RORC (0.33) | — | |
| SCHEMBL3908771 | 0.71 | MELK (0.35) | DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799639-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7538128-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | CRHR1 1878/4885BRD4 2550/4885ORAI1 4362/4885 |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | CRHR1 1806/4885BRD4 1625/4885ORAI1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.